{"classes":[{"categories":[{"measurements":[{"comment":"n/a has been entered because this was not reached","groupId":"OG000","lowerLimit":"14.1","upperLimit":"NA","value":"35.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Progression determined using International Myeloma Working Group criteria, as defined below.\n\nAn increase of \\> 25% from lowest response value one or more of the following:\n\n* Serum M-component and/or (the absolute increase must be \\> 0.5 g/dL)\\*\n* Urine M-component and/or (the absolute increase must be \\> 200 mg/24 h)\n* Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL\n* Bone marrow plasma cell percentage; the absolute percentage must be \\> 10%\n* Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n* Development of hypercalcaemia (corrected serum calcium \\> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder \\*if starting serum M protein is greater then 5 g/dL, absolute increase of 1g/dL is sufficient to determine relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"25 of the 26 patients enrolled onto the were assessed for progression, as one patient expired prior to first response assessment and could not be included in the analysis.","id":"OG000","title":"T-BiRD Therapy (All Patients)"}],"paramType":"MEDIAN","populationDescription":"25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.","reportingStatus":"POSTED","timeFrame":"From start of treatment, to the date of first progression","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}